2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1
2014
A Practical Guide from the International Thymic Malignancy Interest Group (ITMIG) Regarding the Radiographic Assessment of Treatment Response of Thymic Epithelial Tumors Using Modified RECIST Criteria
Benveniste MF, Korst RJ, Rajan A, Detterbeck FC, Marom EM. A Practical Guide from the International Thymic Malignancy Interest Group (ITMIG) Regarding the Radiographic Assessment of Treatment Response of Thymic Epithelial Tumors Using Modified RECIST Criteria. Journal Of Thoracic Oncology 2014, 9: s119-s124. PMID: 25396308, DOI: 10.1097/jto.0000000000000296.Peer-Reviewed Original ResearchConceptsInternational Thymic Malignancy Interest GroupTumor measurementsProgression-free survivalThymic epithelial tumorsStandard outcome measuresMulti-institutional studyAccurate tumor measurementsRECIST criteriaTumor responseClinical trialsRadiographic assessmentTreatment responseEpithelial tumorsOutcome measuresResponse rateInterobserver variabilityThymomaPractical guideInterest group recommendationsChemotherapyPleuraTumors